--(BUSINESS WIRE)--In February 2006 Digilab acquired BioVisioN AG in Hannover, Germany. Digilab is globally commercializing Digilab BioVisioN GmbH’s patented Peptidomics® products and services and generating IP in this space. Digilab-BioVisioN works with companies from the pharmaceutical and diagnostics sectors, analytical instrumentation hardware, software, and consumables suppliers, and academic institutions and government agencies. Digilab has had engagements to discover new biomarkers or drug targets with such companies as AstraZeneca, Boehringer Ingelheim, Merck & Co, Novartis, Novo Nordisk, Roche Diagnostics, Abbott, Johnson & Johnson, and Solvay Pharmaceuticals.
